Viking Global Investors LP and affiliated reporting persons filed Amendment No. 4 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of common stock in Oric Pharmaceuticals, Inc. as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Viking Global Investors LP, O. Andreas Halvorsen, and Rose S. Shabet each reported beneficial ownership of 6,002,989 shares, representing 5.7% of the class.
- No sole voting or dispositive power: All 6,002,989 shares attributed to VGI, Halvorsen, and Shabet are held with shared voting power and shared dispositive power only; sole voting and sole dispositive power are each reported as 0.
- Sub-entity breakdown: Viking Global Opportunities Illiquid Investments Sub-Master LP and related GP entities reported 3,766,111 shares (3.5%), while Viking Global Opportunities Drawdown (Aggregator) LP and related GP entities reported 2,236,878 shares (2.1%).
- Triggering event date: The date of event requiring this filing is stated as September 30, 2026.
- Ten reporting persons: The filing names ten reporting persons in total, including two individuals, O. Andreas Halvorsen (citizen of Norway) and Rose S. Shabet (citizen of the United States), with a shared business address at 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
Viking Global's Amendment No. 4 Ownership Update for Oric Pharmaceuticals
According to the filing, the ten reporting persons collectively constitute Viking Global Investors LP and its affiliated entities. The top-level reporting person, Viking Global Investors LP, is a Delaware limited partnership. Its affiliated general partner and portfolio entities include Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Drawdown GP LLC, and Viking Global Opportunities Drawdown Portfolio GP LLC, all organized in Delaware. The two fund-level limited partnerships, Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, are each organized as Cayman Islands exempted limited partnerships.
The filing discloses that VGI, Halvorsen, and Shabet each report aggregate beneficial ownership of 6,002,989 shares of Oric Pharmaceuticals, Inc. common stock (par value $0.0001 per share, CUSIP 68622P109), equal to 5.7% of the class. Within that total, 3,766,111 shares (3.5%) are attributed to the Opportunities sub-fund entities and 2,236,878 shares (2.1%) to the Drawdown (Aggregator) entities, as reported by the respective GP and portfolio GP entities. In every case, the filing reports sole voting power and sole dispositive power as 0.00, with all voting and dispositive authority held on a shared basis.
The issuer, Oric Pharmaceuticals, Inc., is listed on NASDAQ:ORIC and maintains its principal executive offices at 240 E. Grand Ave, 2nd Floor, South San Francisco, California 94080, according to the filing. This Schedule 13G filing is Amendment No. 4, with the triggering event date stated as September 30, 2026.
What Was Disclosed
Viking Global Investors LP and nine affiliated entities and individuals filed Amendment No. 4 to a Schedule 13G disclosing shared beneficial ownership of 6,002,989 shares, or 5.7%, of Oric Pharmaceuticals, Inc. common stock as of September 30, 2026.





Please wait processing your request...